Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Transplantation ; 107(2): 504-510, 2023 02 01.
Article in English | MEDLINE | ID: mdl-35974436

ABSTRACT

BACKGROUND: Solid organ transplantation is the therapy of choice for many patients with end-stage organ failure; however, recipients must remain on lifelong immunosuppression, leaving them susceptible to infections and cancer. The study of transplant tolerance to prolong graft survival in the absence of immunosuppression has been restricted to recipients of living donor allografts; however, deceased donors significantly outnumber living donors. Mobilization of hematopoietic stem cells (HSCs) from the bone marrow to peripheral blood (PB) could allow PB-HSCs to be used to induce tolerance in deceased donor kidney recipients; however, a major concern is the well-known concomitant mobilization of immune cells into the liver. METHODS: We mobilized HSCs to the PD using a protocol of 2 doses of granulocyte colony-stimulating factor and 1 dose of plerixafor, followed by the collection of mobilized cells via apheresis in 3 deceased donors. The physiological, laboratory, and radiographic parameters were monitored throughout the procedure. Longitudinal biopsies were performed to assess the potential for ectopic liver mobilization. RESULTS: The use of both agents led to the successful mobilization of peripheral blood CD34+ cells, demonstrating the potential for use in transplant tolerance protocols. Increased immune cell trafficking into the liver was not observed, and apheresis of mobilized cells resulted in a uniform decrease in all liver leukocyte subsets. CONCLUSIONS: HSCs can be mobilized and collected from the PB of brain-dead donors. This new approach may facilitate the dissemination of immune tolerance trials beyond living-donor kidney transplantation to deceased-donor transplantation, without sacrificing the transplantability of the liver.


Subject(s)
Blood Component Removal , Hematopoietic Stem Cell Transplantation , Heterocyclic Compounds , Humans , Hematopoietic Stem Cell Mobilization/methods , Hematopoietic Stem Cells , Antigens, CD34/metabolism , Granulocyte Colony-Stimulating Factor/pharmacology , Living Donors , Hematopoietic Stem Cell Transplantation/adverse effects
4.
JAMA ; 323(3): 279-280, 2020 01 21.
Article in English | MEDLINE | ID: mdl-31961416
5.
JAMA ; 322(8): 719-720, 2019 Aug 27.
Article in English | MEDLINE | ID: mdl-31393517
7.
Transplantation ; 102(12): 2096-2100, 2018 12.
Article in English | MEDLINE | ID: mdl-29847504

ABSTRACT

BACKGROUND: Procurement and retransplantation of a previously transplanted kidney reclaim a functioning organ that would otherwise have been discarded. METHODS: Case series of 3 retransplantation cases within the course of 1 calendar year. RESULTS: These cases illustrate how to overcome the immunological, logistical, and technical barriers that have thus far limited the potential of this approach. Within this series, we report kidney reuse weeks and years after the original transplantation, as well as the previously undescribed "living donation of a deceased donor kidney". CONCLUSIONS: Retransplantation of previously transplanted kidneys can be performed successfully and should be considered in the face of the current organ shortage.


Subject(s)
Donor Selection , Kidney Transplantation/methods , Tissue Donors/supply & distribution , Adolescent , Adult , Fatal Outcome , Female , Graft Survival , Histocompatibility , Humans , Kidney Transplantation/adverse effects , Living Donors/supply & distribution , Male , Middle Aged , Reoperation , Risk Factors , Time Factors , Treatment Outcome
8.
Transpl Int ; 27(11): 1175-82, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25052215

ABSTRACT

The disparity between kidney transplant candidates and donors necessitates innovations to increase organ availability. Transporting kidneys allows for living donors and recipients to undergo surgery with a familiar transplant team, city, friends, and family. The effect of shipping kidneys and prolonged cold ischemia time (CIT) with living donor transplantation outcomes is not clearly known. This retrospective matched (age, gender, race, and year of procedure) cohort study compared allograft outcomes for shipped live donor kidney transplants and nonshipped living donor kidney transplants. Fifty-seven shipped live donor kidneys were transplanted from 31 institutions in 26 cities. The mean shipping distance was 1634 miles (range 123-2811) with mean CIT of 12.1 ± 2.8 h. The incidence of delayed graft function in the shipped cohort was 1.8% (1/57) compared to 0% (0/57) in the nonshipped cohort. The 1-year allograft survival was 98% in both cohorts. There were no significant differences between the mean serum creatinine values or the rates of serum creatinine decline in the immediate postoperative period even after adjusted for gender and differences in recipient and donor BMI. Despite prolonged CITs, outcomes for shipped live donor kidney transplants were similar when compared to matched nonshipped living donor kidney transplants.


Subject(s)
Kidney Transplantation , Living Donors , Tissue and Organ Procurement , Adult , Cohort Studies , Cold Ischemia , Creatinine/blood , Delayed Graft Function , Female , Graft Survival , Humans , Male , Middle Aged , Retrospective Studies , Transportation , Unrelated Donors
9.
Transplantation ; 97(9): 881-9, 2014 May 15.
Article in English | MEDLINE | ID: mdl-24827763

ABSTRACT

We describe four solid-organ transplant recipients with donor-derived West Nile virus (WNV) infection (encephalitis 3, asymptomatic 1) from a common donor residing in a region of increased WNV activity. All four transplant recipients had molecular evidence of WNV infection in their serum and/or cerebrospinal fluid (CSF) by reverse transcription polymerase chain reaction (RT-PCR) testing. Serum from the organ donor was positive for WNV IgM but negative for WNV RNA, whereas his lymph node and spleen tissues tested positive for WNV by RT-PCR. Combination therapy included intravenous immunoglobulin (4 cases), interferon (3 cases), fresh frozen plasma with WNV IgG (2 cases), and ribavirin (1 case). Two of the four transplant recipients survived.Review of the 20 published cases of organ-derived WNV infection found that this infection is associated with a high incidence of neuroinvasive disease (70%) and severe morbidity and mortality (30%). Median time to onset of symptomatic WNV infection was 13 days after transplantation (range 5-37 days). Initial unexplained fever unresponsive to antibiotic therapy followed by rapid onset of neurologic deficits was the most common clinical presentation. Confirmation of infection was made by testing serum and CSF for both WNV RNA by RT-PCR and WNV IgM by serological assays. Treatment usually included supportive care, reduction of immunosuppression, and frequent intravenous immunoglobulin. The often negative results for WNV by current RT-PCR and serological assays and the absence of clinical signs of acute infection in donors contribute to the sporadic occurrence of donor-derived WNV infection. Potential organ donors should be assessed for unexplained fever and neurological symptoms, particularly if they reside in areas of increased WNV activity.


Subject(s)
Organ Transplantation/adverse effects , Tissue Donors , West Nile Fever/complications , Antibodies, Viral/blood , Humans , Immunoglobulin M/immunology , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Lung Transplantation/adverse effects , Lymph Nodes/pathology , Male , Middle Aged , RNA, Viral/blood , Spleen/pathology , West Nile Fever/blood , West Nile Fever/cerebrospinal fluid , West Nile Fever/therapy , West Nile virus
13.
Transplantation ; 82(9): 1210-3, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-17102773

ABSTRACT

BACKGROUND: Human T-cell lymphotrophic virus (HTLV) type I has been linked to adult T-cell leukemia/lymphoma (ATL) and HTLV-I associated myelopathy (HAM). Transmission of HTLV by blood and organ transplantation has been documented, with some infections leading to clinical disease. Organ donors are tested for anti-HTLV antibodies and donor suitability is determined primarily by results from enzyme immunoassays (EIA). Confirmatory testing is not routinely performed, and the number of false positive organ donors is unknown. METHODS: In order to investigate the contemporary seroprevalence of anti-HTLV I/II antibodies among solid organ donors and determine the number of false positive samples, we tested 1,408 specimens from prospective organ donors in 2002 and 2003. All specimens were tested for anti-HTLV antibodies by a commercial EIA. Repeatedly reactive specimens underwent confirmatory testing using a commercial Western blot. RESULTS: There were 22 repeatedly EIA reactive donor specimens (1.56%). Five specimens did not undergo further testing because of case shutdown or insufficient sample quantity. HTLV I/II western blot confirmed six positives, whereas five were negative and six were indeterminate. The majority of confirmed specimens were positive for antibodies to HTLV-II. CONCLUSIONS: Our data shows that 29% of initially reactive specimens were false positives. With the increasing demand for organs, the unnecessary rejection of organs that are falsely positive for HTLV antibodies becomes of tremendous importance and stresses the need for timely confirmatory testing for HTLV.


Subject(s)
HTLV-I Antibodies/blood , HTLV-II Antibodies/blood , Tissue Donors , Adult , Blotting, Western , Female , Humans , Male , Middle Aged , Seroepidemiologic Studies
14.
Transplantation ; 81(3): 477-9, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16477238

ABSTRACT

Trypanosoma cruzi, a parasite that causes Chagas' disease, is endemic in parts of Mexico, South America, and Central America. Transmission of T. cruzi infection by solid organ transplantation has been reported in Latin America and recently in the United States. To determine the prevalence of T. cruzi antibodies in Southern California organ donors, 404 samples from deceased organ donors between May 2002 to April 2004 were screened using a qualitative enzyme-linked immunosorbent assay (EIA) and confirmed with an immunofluorescence assay (IFA) available through the Centers for Disease Control (CDC). Six donors were initially reactive by EIA. Three donors were repeatedly reactive after repeat testing and were sent to the CDC for confirmation. One donor (0.25%) had an IFA-confirmed reactivity to anti-T. cruzi antibodies. In areas where there is a high number of immigrants from T. cruzi endemic countries, screening for anti-T. cruzi donor antibodies may be beneficial.


Subject(s)
Antibodies, Protozoan/blood , Chagas Disease/epidemiology , Tissue Donors , Trypanosoma cruzi/immunology , Adult , Animals , California , Chagas Disease/diagnosis , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique , Humans , Male , Middle Aged , Population , Prevalence , Risk , Seroepidemiologic Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...